The Next Step
A similar experiment with dendritic cells was performed on mammals. Scientists found the same result where toIDCs ceased to build-up of the cytokine secretions of the T cells. Moreover, an identical result was observed in the T cells from a patient suffering from SLE.
While a challenge is posed by how cytokines respond on a consistent basis, more research would be needed to further explore this prospective treatment pathway, along with FDA approval for further experimentation on human subjects.
The most effective method of administering this therapy also remains to be seen. Although the concept of targeting and re-engineering DCs is not a new one (previous studies have led to cancer treatment for some forms that are resistant to more common forms of chemotherapy), the most current study has consequently led to the question of how to apply this therapy, whether by injection or some other means.